fda compounding semaglutide warning november 2025 The has received reports of adverse events after patients used compounded versions of semaglutide. Some compounders may also be using unapproved salt forms. Patients should avoid compounded when an FDA-approved FDA crackdown on off-brand Ozempic

We ship to all 50 states Our Chief Chemist and Medical Affairs Manager Bill Fixler, PharmD Letter from Bill on FDA warning to 503A compounders As we discussed, I first wanted to address the attached letter referencing Semaglutide salts from the FDA in October of 2023

Many people with metabolic conditions have significantly depleted Akkermansia populations, which creates a direct rationale for supplementation

An examination of state enforcement actions, Blue Shield policy documents, litigation records, and consumer complaints suggests these experiences follow a consistent pattern rather than isolated administrative error

M.TrappS

References Semaglutide 1-4 Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor